Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach

Cristina Menni, Eric Fauman, Idil Erte, John R B Perry, Gabi Kastenmüller, So Youn Shin, Ann Kristin Petersen, Craig Hyde, Maria Psatha, Kirsten J. Ward, Wei Yuan, Mike Milburn, Colin N A Palmer, Timothy M. Frayling, Jeff Trimmer, Jordana T. Bell, Christian Gieger, Rob P. Mohney, Mary Julia Brosnan, Karsten Suhre & 2 others Nicole Soranzo, Tim D. Spector

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Using a nontargeted metabolomics approach of 447 fasting plasma metabolites, we searched for novel molecular markers that arise before and after hyperglycemia in a large populationbased cohort of 2,204 females (115 type 2 diabetic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjects) from TwinsUK. Forty-two metabolites from three major fuel sources (carbohydrates, lipids, and proteins) were found to significantly correlate with T2D after adjusting for multiple testing; of these, 22 were previously reported as associated with T2D or insulin resistance. Fourteen metabolites were found to be associated with IFG. Among the metabolites identified, the branched-chain keto-acid metabolite 3-methyl-2-oxovalerate was the strongest predictive biomarker for IFG after glucose (odds ratio [OR] 1.65 [95% CI 1.39-1.95], P = 8.46 3 1029) and was moderately heritable (h2 = 0.20). The association was replicated in an independent population (n = 720, OR 1.68 [ 1.34-2.11], P = 6.52 3 1026) and validated in 189 twins with urine metabolomics taken at the same time as plasma (OR 1.87 [1.27-2.75], P = 1 3 1023). Results confirm an important role for catabolism of branched-chain amino acids in T2D and IFG. In conclusion, this T2D-IFG biomarker study has surveyed the broadest panel of nontargeted metabolites to date, revealing both novel and known associated metabolites and providing potential novel targets for clinical prediction and a deeper understanding of causal mechanisms.

Original languageEnglish
Pages (from-to)4270-4276
Number of pages7
JournalDiabetes
Volume62
Issue number12
DOIs
Publication statusPublished - Dec 2013
Externally publishedYes

Fingerprint

Metabolomics
Type 2 Diabetes Mellitus
Fasting
Biomarkers
Glucose
Odds Ratio
Keto Acids
Branched Chain Amino Acids
Hyperglycemia
Insulin Resistance
Carbohydrates
Urine
Lipids
Population
Proteins

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Menni, C., Fauman, E., Erte, I., Perry, J. R. B., Kastenmüller, G., Shin, S. Y., ... Spector, T. D. (2013). Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes, 62(12), 4270-4276. https://doi.org/10.2337/db13-0570

Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. / Menni, Cristina; Fauman, Eric; Erte, Idil; Perry, John R B; Kastenmüller, Gabi; Shin, So Youn; Petersen, Ann Kristin; Hyde, Craig; Psatha, Maria; Ward, Kirsten J.; Yuan, Wei; Milburn, Mike; Palmer, Colin N A; Frayling, Timothy M.; Trimmer, Jeff; Bell, Jordana T.; Gieger, Christian; Mohney, Rob P.; Brosnan, Mary Julia; Suhre, Karsten; Soranzo, Nicole; Spector, Tim D.

In: Diabetes, Vol. 62, No. 12, 12.2013, p. 4270-4276.

Research output: Contribution to journalArticle

Menni, C, Fauman, E, Erte, I, Perry, JRB, Kastenmüller, G, Shin, SY, Petersen, AK, Hyde, C, Psatha, M, Ward, KJ, Yuan, W, Milburn, M, Palmer, CNA, Frayling, TM, Trimmer, J, Bell, JT, Gieger, C, Mohney, RP, Brosnan, MJ, Suhre, K, Soranzo, N & Spector, TD 2013, 'Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach', Diabetes, vol. 62, no. 12, pp. 4270-4276. https://doi.org/10.2337/db13-0570
Menni C, Fauman E, Erte I, Perry JRB, Kastenmüller G, Shin SY et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013 Dec;62(12):4270-4276. https://doi.org/10.2337/db13-0570
Menni, Cristina ; Fauman, Eric ; Erte, Idil ; Perry, John R B ; Kastenmüller, Gabi ; Shin, So Youn ; Petersen, Ann Kristin ; Hyde, Craig ; Psatha, Maria ; Ward, Kirsten J. ; Yuan, Wei ; Milburn, Mike ; Palmer, Colin N A ; Frayling, Timothy M. ; Trimmer, Jeff ; Bell, Jordana T. ; Gieger, Christian ; Mohney, Rob P. ; Brosnan, Mary Julia ; Suhre, Karsten ; Soranzo, Nicole ; Spector, Tim D. / Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. In: Diabetes. 2013 ; Vol. 62, No. 12. pp. 4270-4276.
@article{997ae47662244c5dbca37d7f02bb852e,
title = "Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach",
abstract = "Using a nontargeted metabolomics approach of 447 fasting plasma metabolites, we searched for novel molecular markers that arise before and after hyperglycemia in a large populationbased cohort of 2,204 females (115 type 2 diabetic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjects) from TwinsUK. Forty-two metabolites from three major fuel sources (carbohydrates, lipids, and proteins) were found to significantly correlate with T2D after adjusting for multiple testing; of these, 22 were previously reported as associated with T2D or insulin resistance. Fourteen metabolites were found to be associated with IFG. Among the metabolites identified, the branched-chain keto-acid metabolite 3-methyl-2-oxovalerate was the strongest predictive biomarker for IFG after glucose (odds ratio [OR] 1.65 [95{\%} CI 1.39-1.95], P = 8.46 3 1029) and was moderately heritable (h2 = 0.20). The association was replicated in an independent population (n = 720, OR 1.68 [ 1.34-2.11], P = 6.52 3 1026) and validated in 189 twins with urine metabolomics taken at the same time as plasma (OR 1.87 [1.27-2.75], P = 1 3 1023). Results confirm an important role for catabolism of branched-chain amino acids in T2D and IFG. In conclusion, this T2D-IFG biomarker study has surveyed the broadest panel of nontargeted metabolites to date, revealing both novel and known associated metabolites and providing potential novel targets for clinical prediction and a deeper understanding of causal mechanisms.",
author = "Cristina Menni and Eric Fauman and Idil Erte and Perry, {John R B} and Gabi Kastenm{\"u}ller and Shin, {So Youn} and Petersen, {Ann Kristin} and Craig Hyde and Maria Psatha and Ward, {Kirsten J.} and Wei Yuan and Mike Milburn and Palmer, {Colin N A} and Frayling, {Timothy M.} and Jeff Trimmer and Bell, {Jordana T.} and Christian Gieger and Mohney, {Rob P.} and Brosnan, {Mary Julia} and Karsten Suhre and Nicole Soranzo and Spector, {Tim D.}",
year = "2013",
month = "12",
doi = "10.2337/db13-0570",
language = "English",
volume = "62",
pages = "4270--4276",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach

AU - Menni, Cristina

AU - Fauman, Eric

AU - Erte, Idil

AU - Perry, John R B

AU - Kastenmüller, Gabi

AU - Shin, So Youn

AU - Petersen, Ann Kristin

AU - Hyde, Craig

AU - Psatha, Maria

AU - Ward, Kirsten J.

AU - Yuan, Wei

AU - Milburn, Mike

AU - Palmer, Colin N A

AU - Frayling, Timothy M.

AU - Trimmer, Jeff

AU - Bell, Jordana T.

AU - Gieger, Christian

AU - Mohney, Rob P.

AU - Brosnan, Mary Julia

AU - Suhre, Karsten

AU - Soranzo, Nicole

AU - Spector, Tim D.

PY - 2013/12

Y1 - 2013/12

N2 - Using a nontargeted metabolomics approach of 447 fasting plasma metabolites, we searched for novel molecular markers that arise before and after hyperglycemia in a large populationbased cohort of 2,204 females (115 type 2 diabetic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjects) from TwinsUK. Forty-two metabolites from three major fuel sources (carbohydrates, lipids, and proteins) were found to significantly correlate with T2D after adjusting for multiple testing; of these, 22 were previously reported as associated with T2D or insulin resistance. Fourteen metabolites were found to be associated with IFG. Among the metabolites identified, the branched-chain keto-acid metabolite 3-methyl-2-oxovalerate was the strongest predictive biomarker for IFG after glucose (odds ratio [OR] 1.65 [95% CI 1.39-1.95], P = 8.46 3 1029) and was moderately heritable (h2 = 0.20). The association was replicated in an independent population (n = 720, OR 1.68 [ 1.34-2.11], P = 6.52 3 1026) and validated in 189 twins with urine metabolomics taken at the same time as plasma (OR 1.87 [1.27-2.75], P = 1 3 1023). Results confirm an important role for catabolism of branched-chain amino acids in T2D and IFG. In conclusion, this T2D-IFG biomarker study has surveyed the broadest panel of nontargeted metabolites to date, revealing both novel and known associated metabolites and providing potential novel targets for clinical prediction and a deeper understanding of causal mechanisms.

AB - Using a nontargeted metabolomics approach of 447 fasting plasma metabolites, we searched for novel molecular markers that arise before and after hyperglycemia in a large populationbased cohort of 2,204 females (115 type 2 diabetic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjects) from TwinsUK. Forty-two metabolites from three major fuel sources (carbohydrates, lipids, and proteins) were found to significantly correlate with T2D after adjusting for multiple testing; of these, 22 were previously reported as associated with T2D or insulin resistance. Fourteen metabolites were found to be associated with IFG. Among the metabolites identified, the branched-chain keto-acid metabolite 3-methyl-2-oxovalerate was the strongest predictive biomarker for IFG after glucose (odds ratio [OR] 1.65 [95% CI 1.39-1.95], P = 8.46 3 1029) and was moderately heritable (h2 = 0.20). The association was replicated in an independent population (n = 720, OR 1.68 [ 1.34-2.11], P = 6.52 3 1026) and validated in 189 twins with urine metabolomics taken at the same time as plasma (OR 1.87 [1.27-2.75], P = 1 3 1023). Results confirm an important role for catabolism of branched-chain amino acids in T2D and IFG. In conclusion, this T2D-IFG biomarker study has surveyed the broadest panel of nontargeted metabolites to date, revealing both novel and known associated metabolites and providing potential novel targets for clinical prediction and a deeper understanding of causal mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84890185204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890185204&partnerID=8YFLogxK

U2 - 10.2337/db13-0570

DO - 10.2337/db13-0570

M3 - Article

VL - 62

SP - 4270

EP - 4276

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -